(Arthritis Research Therapy[TA])
6,270 results
  • Dysregulated IL-6 pathway activity in idiopathic inflammatory myopathies. [Journal Article]
    Arthritis Res Ther. 2026 Jul 21. [Online ahead of print]Srpčič A, Urzi F, … Perdan Pirkmajer KAR
  • CONCLUSIONS: IIM is characterised by enhanced systemic IL-6 pathway activity that is not explained by circulating IL-6 levels alone but rather reflects a dysregulated cytokine milieu. Reduced levels of endogenous anti-IL-6 autoantibodies, together with their neutralising capacity, suggest a potential role in modulating IL-6 bioactivity.
  • Evaluating clinical heterogeneity in relapsing polychondritis through unsupervised cluster analysis. [Journal Article]
    Arthritis Res Ther. 2026 Jul 11. [Online ahead of print]Pan W, Yin L, … Sun HAR
  • CONCLUSIONS: This study confirms that relapsing polychondritis is not a single-dimensional disease, but a clinical syndrome with significant heterogeneity. Random forest analysis further identifies that systemic inflammation markers (CRP, CAR, ESR) and sensory organ involvement (hearing impairment and inner ear dysfunction) as the most critical driving factors for distinguishing these subtypes.
  • Plasma proteome differences between giant cell arteritis and polymyalgia rheumatica: a pilot study. [Journal Article]
    Arthritis Res Ther. 2026 Jul 01. [Online ahead of print]Seidlberger S, Castañeda S, … Santos-Sierra SAR
  • CONCLUSIONS: Active PMR and active GCA patients share an unexpectedly small plasma proteome signature related to immune activation (8.9%: 13 proteins). Instead, active PMR is characterized by distinct erythrocyte and muscle contraction proteome changes, whereas active GCA appears driven by mitochondrial and clotting cascade alterations. Prospective, longitudinal validation studies of the described proteomic signatures might support the clinical classification of both diseases.